New Weight-Loss drug candidate enters early human testing
NCT ID NCT07170319
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This early-stage study tests a new drug called IBI3032 in people who are overweight or have obesity. The main goal is to check if the drug is safe and how the body processes it over four weeks of treatment. About 79 participants will receive either the drug or a placebo. This is a first step to see if IBI3032 could help control weight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Frist Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
Conditions
Explore the condition pages connected to this study.